Overview
IsoPlexis provides single-cell multiplexed proteomics platforms that enable simultaneous detection of 40+ proteins secreted from individual immune cells. Their IsoCode chip and IsoLight system allow pharmaceutical and biotech companies to characterize cellular functional heterogeneity for precision medicine applications in cancer immunology, cell and gene therapy, and infectious disease. The technology delivers patient-specific biomarker insights that traditional bulk analysis cannot capture, supporting personalized treatment selection and immunotherapy patient profiling.
Frequently asked questions
- What proteins can IsoPlexis simultaneously detect from single cells?
- IsoPlexis can simultaneously measure up to 40-42 immune effector function proteins secreted from individual live immune cells using their single-cell IsoCode chip and fluorescent ELISA-based assay platform.
- What sample types does IsoPlexis analyze?
- IsoPlexis analyzes cell subsets from peripheral blood, bone marrow, and tumor tissues, enabling researchers to characterize cellular products and functional heterogeneity across diverse sample sources.
- How does IsoPlexis differ from competing single-cell analysis technologies?
- Unlike bulk analysis methods, IsoPlexis reads each cell individually rather than averaging large populations, providing highly precise per-cell data that reveals functional heterogeneity and prevents patient data from appearing uniform.
- What therapeutic areas does IsoPlexis support?
- IsoPlexis focuses on cell and gene therapy, cancer immunology, and infectious disease applications, enabling more patient-specific and long-lasting treatment development through cellular proteomics.
- Is the IsoPlexis platform easy to use?
- Yes, the IsoLight platform features easy-to-use instrumentation and software. Samples are placed on the device surface, cells are distributed to microscopic chambers for individual analysis, and data is read via computer interface.